KLRK1 as a prognostic biomarker for lung adenocarcinoma cancer

被引:0
|
作者
Yanan Zhang
Zeyang Chen
Aifang Jiang
Guanqi Gao
机构
[1] Weifang Medical University,Clinical Medical College
[2] Linyi People’s Hospital,Clinical Medical College
[3] Qingdao University,undefined
[4] Weifang Medical University,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Lung cancer is one of the most common malignancy worldwide and causes estimated 1.6 million deaths each year. Cancer immunosurveillance has been found to play an important role in lung cancer and may be related with its prognosis. KLRK1, encoding NKG2D, is a homodimeric lectin-like receptor. However, there has not been one research of KLRK1 as a biomarker in lung cancer. Data including patients` clinical characteristics and RNAseq information of KLRK1 from TCGA were downloaded. A total of 1019 patients with lung cancer were included in this study, among which 407 patients were female and 611 patients were male. Evaluations of mRNA expression, diagnostic value by ROC (receiver operating characteristic) curves and prognostic value by survival curve, Cox model and subgroup analysis were performed. The level of KLRK1 expression in lung adenocarcinoma cancer tissues and normal lung tissues was detected by qRT-PCR. The CCK-8 assay investigated the proliferation rate and the wound healing assay assessed the migratory ability in vitro. The expression of KLRK1 in tumor was lower than that in normal tissue. KLRK1 expression was associated with gender, histologic grade, stage, T classification and vital status. Patients with high KLRK1 expression presented an improved overall survival (P = 0.0036) and relapse free survival (P = 0.0031). KLRK1 was found to have significant prognostic value in lung adenocarcinoma (P = 0.015), stage I/II (P = 0.03), older patients (P = 0.0052), and male (P = 0.0047) by subgroup overall survival analysis, and in lung adenocarcinoma (P = 0.0094), stage I/II (P = 0.0076), older patients (P = 0.0072), and male (P = 0.0033) by subgroup relapse free survival analysis. Lung adenocarcinoma cancer patients with high KLRK1 expression presented an improved overall survival (P = 0.015) and relapse free survival (P = 0.0094). In vitro studies indicated that KLRK1 inhibited tumor cell proliferation and migration. KLRK1 was an independent prognostic factor and high KLRK1 expression indicated a better overall and relapse free survival. KLRK1 may be a prognostic biomarker for lung adenocarcinoma cancer.
引用
收藏
相关论文
共 50 条
  • [41] FHL1 as a novel prognostic biomarker and correlation with immune infiltration levels in lung adenocarcinoma
    Zhang, Jingtao
    Li, Haitao
    Guo, Minghao
    Zhang, Jing
    Zhang, Guangming
    Sun, Ning
    Feng, Yuyuan
    Cui, Wenqiang
    Xu, Fei
    IMMUNOTHERAPY, 2023, 15 (04) : 235 - 252
  • [42] VIPR1 as a novel prognostic biomarker and its correlation with immune infiltrates in lung adenocarcinoma
    Al-Kraimeen, L. M.
    Ababneh, O.
    Al-Kraimeen, Y.
    Ayoub, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1324 - S1325
  • [43] GTSE1: A potential prognostic and diagnostic biomarker in various tumors including lung adenocarcinoma
    Yan, Guanqiang
    Li, Guosheng
    Gao, Xiang
    Liu, Jun
    Li, Yue
    Li, Jingxiao
    Zhou, Huafu
    CLINICAL RESPIRATORY JOURNAL, 2024, 18 (05):
  • [44] TBX5-AS1, an enhancer RNA, is a potential novel prognostic biomarker for lung adenocarcinoma
    Cheng, Lin
    Han, Tong
    Chen, Bolin
    Nie, Kechao
    Peng, Weijun
    BMC CANCER, 2021, 21 (01)
  • [45] Integrative analysis disclosing UQCRC1 as a potential prognostic and immunological biomarker of lung adenocarcinoma
    Ling, Lv
    Peng, Cong
    Lin, Sheng
    Chen, Yuanhang
    Deng, Min
    Qiu, Huisi
    Huang, Yuanfeng
    PATHOLOGY RESEARCH AND PRACTICE, 2025, 266
  • [46] UBE2Q1 as a novel cancer biomarker for lung adenocarcinoma
    Jiang, Wei
    Wang, Yuchao
    Zou, Jue
    Li, Li
    Xu, Chunhua
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2025, 369 (03): : 359 - 365
  • [47] TBX5-AS1, an enhancer RNA, is a potential novel prognostic biomarker for lung adenocarcinoma
    Lin Cheng
    Tong Han
    Bolin Chen
    Kechao Nie
    Weijun Peng
    BMC Cancer, 21
  • [48] CYP4B1 is a prognostic biomarker and potential therapeutic target in lung adenocarcinoma
    Liu, Xiaoling
    Jia, Yichen
    Shi, Changyuan
    Kong, Dechen
    Wu, Yuanming
    Zhang, Tiantian
    Wei, Anjie
    Wang, Dan
    PLOS ONE, 2021, 16 (02):
  • [49] LRMP Associates With Immune Infiltrates and Acts as a Prognostic Biomarker in Lung Adenocarcinoma
    Jin, X.
    Zhou, N.
    Zu, L.
    He, J.
    Yang, L.
    Zhu, Y.
    Sun, X.
    Xu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1144 - S1144
  • [50] Prognostic biomarker discovery based on proteome landscape of Chinese lung adenocarcinoma
    Huang, Yuqi
    Ma, Sheng
    Xu, Jun-Yu
    Qian, Kun
    Wang, Yaru
    Zhang, Yi
    Tan, Minjia
    Xiao, Ting
    CLINICAL PROTEOMICS, 2024, 21 (01)